102P Long-term prediction of clinical outcomes by the 21-gene test in HR+ HER2- breast cancer patients with residual disease after neoadjuvant chemotherapy

Neoadjuvant chemotherapy (NAC) is increasingly used for treatment of early-stage breast cancer patients, with HR+, HER2- tumors showing the lowest rate of pathological complete response (pCR). Therefore, standardized tools result essential to identify those HR+, HER2- breast cancer patients with residual disease in the breast and/or axillary nodes who are at increased risk of distant recurrence after treatment with NAC.